Press release
Uveitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight
Uveitis Clinical Trials
"Uveitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.
The Uveitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Uveitis Pipeline Report:
• Uveitis Companies across the globe are diligently working toward developing novel Uveitis treatment therapies with a considerable amount of success over the years.
• Uveitis companies working in the treatment market are Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others, are developing therapies for the Uveitis treatment
• Emerging Uveitis therapies in the different phases of clinical trials are- Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others are expected to have a significant impact on the Uveitis market in the coming years.
• In August 2023, Tarsier Pharma, an advanced clinical-stage biotechnology company focused on developing dazdotuftide (previously TRS), a groundbreaking New Chemical Entity for individuals with immune-mediated diseases, has disclosed findings from the TRS4VISION Trial, which investigated noninfectious anterior uveitis. Although the primary endpoint was not achieved, a subsequent analysis of the data reveals an eagerly awaited clinical profile, showcasing a combination of safety and effective resolution of inflammation. This outcome holds promise for the treatment of noninfectious uveitis, particularly in managing uveitic glaucoma.
• In April 2023, The World Health Organization (WHO) has placed Tarsier Pharma Ltd., a late-stage pharmaceutical business, on the INN Recommended List and awarded its first-in-class immunomodulator TRS an International Nonproprietary Name (INN) of "Dazdotuftide."
• In September 2021, A Phase III randomized, active-controlled, double-masked trial was started by Tarsier Pharma to assess the safety and effectiveness of TRS01 eye drops in treating patients with active non-infectious anterior uveitis, including those with uveitic glaucoma.
Uveitis Overview
The illness condition known as uveitis causes inflammation in the eyes. A wide range of disease types together known as uveitis have been estimated to cause 10% of blindness. Acute, intermediate, posterior, and panuveitis are the four main categories of uveitis according to the eye's anatomical involvement.
Get a Free Sample PDF Report to know more about Uveitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Uveitis Drugs Under Different Phases of Clinical Development Include:
• Laquinimod: Active Biotech AB
• EYS606: Eyevensys
• ESK-001: Alumis Inc
• Baricitinib: Eli Lilly and Company
• TRS01: Tarsier Pharma
Uveitis Route of Administration
Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Uveitis Molecule Type
Uveitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Uveitis Pipeline Therapeutics Assessment
• Uveitis Assessment by Product Type
• Uveitis By Stage and Product Type
• Uveitis Assessment by Route of Administration
• Uveitis By Stage and Route of Administration
• Uveitis Assessment by Molecule Type
• Uveitis by Stage and Molecule Type
DelveInsight's Uveitis Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Uveitis product details are provided in the report. Download the Uveitis pipeline report to learn more about the emerging Uveitis therapies at:
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Uveitis Therapeutics Market include:
Key companies developing therapies for Uveitis are - Novartis AG, Bausch Health Inc., AbbVie Inc., Eyegate Pharmaceuticals, Inc., Alimera Science Inc., EyePoint Pharmaceuticals, Santen Pharmaceuticals, Clearside Biomedical inc., and others.
Uveitis Pipeline Analysis:
The Uveitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Uveitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveitis Treatment.
• Uveitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Uveitis drugs and therapies-
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Uveitis Pipeline Market Drivers
• Increasing Prevalence of Uveitis, increase in Research and developmental Activities are some of the important factors that are fueling the Uveitis Market.
Uveitis Pipeline Market Barriers
• However, high Cost associated with the treatment, lack of skilled professionals and other factors are creating obstacles in the Uveitis Market growth.
Scope of Uveitis Pipeline Drug Insight
• Coverage: Global
• Key Uveitis Companies: Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others
• Key Uveitis Therapies: Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others
• Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
• Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers
Request for Sample PDF Report for Uveitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Uveitis Report Introduction
2. Uveitis Executive Summary
3. Uveitis Overview
4. Uveitis- Analytical Perspective In-depth Commercial Assessment
5. Uveitis Pipeline Therapeutics
6. Uveitis Late Stage Products (Phase II/III)
7. Uveitis Mid Stage Products (Phase II)
8. Uveitis Early Stage Products (Phase I)
9. Uveitis Preclinical Stage Products
10. Uveitis Therapeutics Assessment
11. Uveitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Uveitis Key Companies
14. Uveitis Key Products
15. Uveitis Unmet Needs
16 . Uveitis Market Drivers and Barriers
17. Uveitis Future Perspectives and Conclusion
18. Uveitis Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Healthcare Pipeline Analysis: https://www.delveinsight.com/consulting/pipeline-assessment-services
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Menorrhalgia Market Size: https://www.delveinsight.com/report-store/menorrhalgia-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-type-2-market-insight
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acanthamoeba Keratitis Market: https://www.delveinsight.com/report-store/acanthamoeba-keratitis-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/merger-and-acquisition
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight here
News-ID: 3850042 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Uveitis
Uveitis Market : An Overview Report
Introduction:
Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye. It can lead to vision impairment or even blindness if left untreated. Uveitis is categorized into different types, including anterior, intermediate, posterior, and panuveitis, depending on the part of the eye affected. The condition can be caused by infections, autoimmune diseases, or trauma. With increasing cases of autoimmune disorders and infectious diseases, the prevalence of uveitis…
Uveitis Treatment Market Size, Share | Trend 2030
Exclusive Report by Ameco Research: Uveitis Treatment Market Size Projected to Reach USD 2 Billion by 2030, Growing at 6% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Uveitis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality market research…
Uveitis - Drug Pipeline Landscape, 2022
New York, Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of…
Uveitis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based…
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
